MGTX - MeiraGTx Holdings plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.02
+0.50 (+2.44%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close20.52
Open20.61
Bid20.94 x 1200
Ask20.95 x 800
Day's Range20.24 - 21.22
52 Week Range8.53 - 30.23
Volume213,805
Avg. Volume178,963
Market Cap769M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.29
Earnings DateNov 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.25
  • Hedge Funds Have Never Been This Bullish On MeiraGTx Holdings plc (MGTX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On MeiraGTx Holdings plc (MGTX)

    Is MeiraGTx Holdings plc (NASDAQ:MGTX) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

  • GlobeNewswire

    MeiraGTx to Host Parkinson’s Disease R&D Day in New York

    LONDON and NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a Parkinson’s disease-focused R&D Day on December 13, 2019 from 9:00-11:30 a.m. ET in New York. The program will focus on MeiraGTx’s investigational gene therapy candidate AAV-GAD in development for the treatment of Parkinson’s disease. MeiraGTx’s president and CEO, Alexandria Forbes, Ph.D., will be joined by additional members of the senior leadership team, in addition to leading clinicians and researchers, to discuss the current Parkinson’s disease treatment landscape and results from Phase 1 and Phase 2 clinical trials of AAV-GAD.

  • Gene Therapy the Next Best Thing: Here's Why (Revised)
    Zacks

    Gene Therapy the Next Best Thing: Here's Why (Revised)

    Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

  • GlobeNewswire

    MeiraGTx to Present at Upcoming Healthcare Conferences

    LONDON and NEW YORK, Nov. 26, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced.

  • Can You Imagine How MeiraGTx Holdings's (NASDAQ:MGTX) Shareholders Feel About The 21% Share Price Increase?
    Simply Wall St.

    Can You Imagine How MeiraGTx Holdings's (NASDAQ:MGTX) Shareholders Feel About The 21% Share Price Increase?

    It hasn't been the best quarter for MeiraGTx Holdings plc (NASDAQ:MGTX) shareholders, since the share price has fallen...

  • GlobeNewswire

    MeiraGTx Reports Third Quarter 2019 Financial Results

    LONDON and NEW YORK, Nov. 07, 2019 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial.

  • Is MeiraGTx Holdings plc (MGTX) Going to Burn These Hedge Funds?
    Insider Monkey

    Is MeiraGTx Holdings plc (MGTX) Going to Burn These Hedge Funds?

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]

  • Globenewswire Test

    MeiraGTx to Present at Upcoming Scientific and Investor Conferences

    LONDON and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company will present at the following upcoming events: 3rd Annual Chardan Genetic Medicines Conference in New YorkAlexandria Forbes, Ph.D., president and chief executive officer, will participate in a fireside chat at the Chardan Genetic Medicines Conference on October 7, 2019 from 1:30 p.m. – 1:55 p.m. ET, and will participate on a panel titled “Emerging Disease Areas in Gene Therapy” on October 7, 2019 from 9:30 a.m. – 10:15 a.m. ET.A live webcast of the fireside chat can be accessed through the Investors page of the Company's website at https://investors.meiragtx.com. A replay of the webcast will be available on the Company's website for 30 days following the live presentation.Jefferies Gene Therapy/Editing Summit in New YorkDr. Forbes will participate on a panel at the Jefferies Gene Therapy/Editing Summit on October 8, 2019 from 10:20 a.m. – 11:10 a.m. ET titled “Manufacturing, Dose, and Durability in Gene Therapy”.American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco Michel Michaelides, BSc MB BS MD(Res) FRCOphth FACS, trial investigator, Consultant Ophthalmologist, Moorfields Eye Hospital and Professor of Ophthalmology, University College London, will present data at the Retina Subspecialty Day of the AAO Annual Meeting on the Company’s Phase 1/2 open-label, multi-center, dose-finding trial evaluating AAV-RPE65 in patients with RPE65-associated retinal dystrophy on October 12, 2019 at 9:17 a.m. PT.Professor Michaelides will also present a poster titled “Development and Validation of a Vision-Guided Mobility Assessment for RPE65-Associated Retinal Dystrophy” in a poster discussion session on October 14, 2019 at 12:30 p.m. PT. The poster describes the validation of a novel mobility assessment that is sensitive to the visual impairment of individuals with RPE65-associated retinal dystrophy.In the Phase 1/2 trial of AAV-RPE65, subjects navigated this mobility test at timepoints before and after treatment in order to assess the impact of AAV-RPE65 on functional vision.Conference Call and Webcast Information MeiraGTx will host a conference call and live webcast following Professor Michaelides’ presentation at AAO to review the data from the Phase 1/2 trial on October 12, 2019 at 5:30 p.m. PT. The live webcast can be accessed by visiting the Investors page of the Company’s website at https://investors.meiragtx.com. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1 (866) 796-1272 (U.S.) or 1 (409) 937-8924 (International) to listen to the live conference call. The conference ID number for the live call is 5291617. A replay of the webcast and accompanying presentation materials will be available on the Company’s website for 30 days following the live conference call.About MeiraGTx MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia and xerophthalmia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. For more information, please visit www.meiragtx.com.Contacts  Investors: MeiraGTx Elizabeth Broder (646) 860-7983 Investors@meiragtx.com  or Media: W2O pure Christiana Pascale (212) 257-6722 cpascale@purecommunications.com

  • GlobeNewswire

    MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences

    MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that clinical data updates from the Company’s Phase 1/2 trial of AAV-RPE65 will be presented at two upcoming medical meetings. The Phase 1/2 open-label, multi-center, dose-finding trial evaluated AAV-RPE65 in patients with retinal dystrophy associated with disease-causing variants in the RPE65 gene, a condition that causes severe sight impairment beginning at birth. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to treat RPE65-deficiency, and optimized for transduction efficiency, potency and stability.

  • Could MeiraGTx Holdings plc's (NASDAQ:MGTX) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could MeiraGTx Holdings plc's (NASDAQ:MGTX) Investor Composition Influence The Stock Price?

    Every investor in MeiraGTx Holdings plc (NASDAQ:MGTX) should be aware of the most powerful shareholder groups...

  • GlobeNewswire

    MeiraGTx Announces Pricing of Public Offering of Ordinary Shares

    LONDON and NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten public offering of 3,200,000 of its ordinary shares at a public offering price of $23.50 per share. In addition, MeiraGTx has granted the underwriters a 30-day option to purchase up to an additional 480,000 of its ordinary shares at the public offering price, less underwriting discounts and commissions. BofA Merrill Lynch, Piper Jaffray and Chardan are acting as joint book-running managers of the offering.

  • GlobeNewswire

    MeiraGTx Announces Proposed Public Offering of Ordinary Shares

    LONDON and NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an underwritten public offering of $75 million of its ordinary shares. In connection with the offering, MeiraGTx intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in the public offering. All of the ordinary shares are being offered by MeiraGTx.

  • GlobeNewswire

    MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    LONDON and NEW YORK, Aug. 07, 2019 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial.

  • Why McEwen Mining, MeiraGTx Holdings, and Electronic Arts Slumped Today
    Motley Fool

    Why McEwen Mining, MeiraGTx Holdings, and Electronic Arts Slumped Today

    Find out why these stocks had significant drops.

  • 3 Small-Cap Biotech Stocks That Soared Last Week
    Motley Fool

    3 Small-Cap Biotech Stocks That Soared Last Week

    It was a great week for these three stocks, but can they continue climbing?

  • Estimating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)
    Simply Wall St.

    Estimating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)

    How far off is MeiraGTx Holdings plc (NASDAQ:MGTX) from its intrinsic value? Using the most recent financial data...

  • 3 Biotech Stocks That Soared Last Week: Are They Buys?
    Motley Fool

    3 Biotech Stocks That Soared Last Week: Are They Buys?

    Can these high-flying biotech stocks keep the momentum going?

  • Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout
    Investor's Business Daily

    Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout

    Dow Jones component Johnson & Johnson could buy out biotech stock MeiraGTx for its efforts in gene therapy, an analyst suggested Friday. MeiraGTx is working on treatments for eye diseases.

  • GlobeNewswire

    MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update

    • Positive 6-month results from Phase 1/2 clinical trial of AAV-RPE65 • Enrollment completed in the Phase 1/2 clinical trial investigating AAV-CNGB3 gene therapy for the.

  • GlobeNewswire

    MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency

    LONDON and NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive data from a Phase 1/2 dose escalation trial of AAV-RPE65, the Company’s investigational gene therapy for the treatment of RPE65-deficiency, a condition that causes blindness. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to treat RPE65-deficiency, and optimized for transduction efficiency, potency and stability. The trial enrolled 15 patients, including nine young adults (aged 16-24 years old) across three dose escalation cohorts, and six children (aged 5-12 years old) in a pediatric expansion cohort.

  • GlobeNewswire

    MeiraGTx Appoints Nicole Seligman to Board of Directors

    LONDON and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Nicole Seligman to its Board of Directors. Ms. Seligman is an accomplished leader with extensive executive, legal, compliance and governance experience. “We are delighted to welcome Nicole to the MeiraGTx Board of Directors at this exciting time for the company,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.

  • GlobeNewswire

    MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference

    LONDON and NEW YORK, May 06, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes,.

  • GlobeNewswire

    MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019

    LONDON and NEW YORK, April 25, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced a pre-clinical poster.